The average one-year price target for Passage Bio (NasdaqCM:PASG) has been revised to $40.39 / share. This is an increase of 21.85% from the prior estimate of $33.15 dated November 14, 2025.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $10.10 to a high of $71.40 / share. The average price target represents an increase of 338.57% from the latest reported closing price of $9.21 / share.
What is the Fund Sentiment?
There are 31 funds or institutions reporting positions in Passage Bio. This is an increase of 23 owner(s) or 287.50% in the last quarter. Average portfolio weight of all funds dedicated to PASG is 0.04%, an increase of 2,194,847.63%. Total shares owned by institutions increased in the last three months by 49,931.78% to 1,561K shares. 
The put/call ratio of PASG is 0.03, indicating a bullish outlook.
What are Other Shareholders Doing?
Lynx1 Capital Management holds 624K shares representing 19.62% ownership of the company.
Vestal Point Capital holds 305K shares representing 9.60% ownership of the company.
Erste Asset Management holds 123K shares representing 3.86% ownership of the company.
Renaissance Technologies holds 101K shares representing 3.17% ownership of the company.
Tang Capital Management holds 75K shares representing 2.36% ownership of the company.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
